NICE Guidelines Update: Cannabis-Based Medicines for Chronic Pain
The National Institute for Health and Care Excellence has updated its clinical guidance on cannabis-based medicinal products for adults living with chronic pain conditions.
The National Institute for Health and Care Excellence (NICE) has released updated clinical guidance covering the use of cannabis-based medicinal products (CBMPs) for adults suffering from chronic pain. The revision follows a comprehensive evidence review conducted over 18 months, incorporating data from UK specialist clinics and international registry studies.
What Has Changed
The updated guidance broadens the conditions under which CBMPs may be considered appropriate treatment options. Specialist physicians can now recommend cannabis-based therapies for patients who have not responded adequately to at least two conventional analgesic regimens, including opioids and gabapentinoids.
Prescriber Requirements
- Prescription must originate from a registered specialist in pain medicine, neurology, or palliative care
- Patients must be enrolled in an approved outcome-monitoring programme
- Regular reassessment at 12-week intervals is now mandatory
- Pharmacovigilance reporting required for all adverse events
Patient Impact
Patient advocacy groups have broadly welcomed the updated guidance. Organisations representing those with fibromyalgia, neuropathic pain, and complex regional pain syndrome say the changes remove significant barriers that previously prevented specialist referrals.
"This guidance is a meaningful step forward. Patients who have exhausted conventional options deserve access to evidence-based alternatives under proper clinical supervision."
The guidance does not extend to primary care prescribing. General practitioners remain unable to initiate CBMP treatment, though they may continue prescriptions following specialist review. NICE has indicated it will reassess this restriction once further real-world evidence accumulates from UK registry data.
